Evaluation of Parsortix PR1 and PX+ Systems for the Isolation of Circulating Tumour Cells in Patients With Resectable Lung Cancer

• V.M. Saini,
• E. Oner,
• S. Hurley,
• S. Nicholson,
• L. O'Driscoll,
• S. Finn,
• G. Fitzmaurice,
• K. Gately

Affiliations

V.M. Saini

Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin & St James’s Hospital, Dublin, Ireland

E. Oner

Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin & St James’s Hospital, Dublin, Ireland

S. Hurley

Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin & St James’s Hospital, Dublin, Ireland

S. Nicholson

Histopathology, St James’s Hospital, Dublin, Ireland

L. O'Driscoll

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

S. Finn

Histopathology, St James’s Hospital, Dublin, Ireland

G. Fitzmaurice

Cardiothoracic surgery, St James’s Hospital, Dublin, Ireland

K. Gately

Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin & St James’s Hospital, Dublin, Ireland